Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 406 participants.

Also called NCT03353350

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 406 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03353350
Other papers using this trial's data
  • Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial Diabetes care, 2022-07-07 DOI, PubMed 35671039, PMC9274225 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Poland, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03353350. Randomized; quadruple masking; primary purpose treatment. Start 2017-12-05 (actual); primary completion 2020-01-29 (actual). Results posted on 2022-01-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Acronym
AMPLITUDE-M
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
efpeglenatide (SAR439977)
Intervention (Drug)
placebo
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03353350
Content hash
34fde62ce63d1c78d8d30453a742969b20cce8036ff590412a65c58d4ee3ed2a